Volume 02 | February 12, 2018
RxReins is a dedicated Managing General Underwriter (MGU) specializing in prescription stop loss insurance group benefit plans. We work closely with Brokers, TPA's and PBM's providing the best available products from multiple A-rated carriers in all fifty states .
MONTHLY NEWS AND UPDATES!
Once a Week Injections for Hemophilia Approved by FDA

" A costly new Roche Holding AG drug to treat the bleeding disorder Hemophilia A could significantly reduce healthcare expenses for certain patients. The drug, Hemlibra, or emicizumab, was approved by the Food and Drug Administration in November as a once-weekly injection for adults and pediatric patients with hemophilia A who have developed inhibitors, or resistance, to other treatments."

Hemlibra is an antibody designed to activate the natural coagulation cascade and restore the blood clotting process for Hemophilia A.

Trending Events...
Big Pharma Greets Hundreds Of Ex-Federal Workers At The Revolving Door

"Nearly 340 former congressional staffers now work for pharmaceutical companies or their lobbying firms, according to data analyzed by KHN and provided by Legistorm. The analysis showed, more than a dozen former drug industry employees now have jobs on Capitol Hill — often on committees that handle health care policy.

"In many cases, former congressional staffers who now work for drug companies return to the Hill to lobby former co-workers or employees. The deep ties raise concerns that pharmaceutical companies could wield undue influence over drug-related legislation or government policy."

Light Therapy Could Improve Sleep Quality for Patients with Cancer

"Sleep disturbances occur at a much higher rate for patients with cancer compared with the general population, with approximately 23% to 44% of patients with cancer experiencing insomnia. In a pilot study, a systematic light exposure intervention with a mixed group of fatigued cancer survivors was significantly more effective than comparison dim light exposure in improving sleep efficiency," said lead author Lisa M. Wu, PhD.

Report Raises Concerns About HEP C Drugs

"Hepatitis C affects more than 2 million people in the United States and millions more worldwide. The disease can also be difficult to diagnosis, persisting for decades without symptoms and eventually progressing to cirrhosis of increasing severity."

"Statements made by the US Food and Drug Administration (FDA) in October 2016, in which they note the first major safety problem linked to nine new direct-acting antiviral drugs for hepatitis C, including sofosbuvir (SOVALDI), ledipasvir-sofosbuvir (HARVONI), and simeprevir (OLYSIO). While each drug has demonstrated success at suppressing hepatitis C virus to undetectable levels in most patients, they have also been linked to the reactivation of hepatitis B, with severe health consequences, including liver transplant and death."

ELMC Undergoes Brand Evolution to Include Rx Risk Solutions Division

“As part of its brand evolution, the company has adopted a new name that better reflects its corporate mission - ELMC Risk Solutions. In addition, both Rx Reins and Adler Rx Solutions will operate under the new ELMC Rx Solutions division”

Guaranteed Cost Rx!
If an employer is risk adverse and still wants the benefits of self-funding their employee health benefits consider trying our Guaranteed Cost program.

To learn more sign up for our webinar Click to Register , or visit our website. RxReins.com
Upcoming Events
Next month, RxReins will be exhibiting at PBMI 2018 in Palm Springs, CA. Be sure to stop by our booth #403, or if you're interested in connecting with us at PBMI click the link below.

Crystal Williams, the President of RxReins will be attending SIIA 2018 in Charleston, SC. Just click the link below if you would like to schedule meeting with her.
RxReins, LLC | 888.797.3467 | Stoploss@Rxreins.coml | www.rxreins.com